BJDXHealthcare · Medical Devices

BJDX Stock Forecast: Bluejay Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026

$0.54

0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 31 Oct 2026 — in the weakest quartile.

Market cap

$2.5M

Ticker Nerd rank

20/ 100

Median analyst target

—

Analysts covering

Revenue$0.0

Operating income−$2.3M

Net income−$2.3M

Free cash flow−$1.6M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−7.7%

−36.8%

YTD

−79.8%

−93.9%

From 52W high

−93.9%

From 52W low

0.0%

$0.54

$8.80

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

BJDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bluejay Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026

20/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Volatility

Issuance

Momentum

Growth

Revisions

Quality

Value

Size (98): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BJDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BJDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
3 Aug 2023	Dawson James	Downgrade	Neutral	—
12 Jan 2022	Dawson James	Initiates	Buy	$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BJDX appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

BJDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Bluejay Diagnostics, Inc. returned −93.9% against +12.4% for the S&P 500, dividends included.

BJDX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BJDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Bluejay Diagnostics, Inc. (BJDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: —
Price / book: 0.1×
EV / EBITDA: 1.0×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −98.9%
Return on assets: −51.1%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bluejay Diagnostics, Inc. (BJDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Bluejay Diagnostics, Inc. has a market value of $2.5M and an enterprise value of −$7.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$7.3M.
Free cash flow in the twelve months to 30 June 2026: −$6.2M.
Shares outstanding: 1.0M.
Trailing P/E: 0.0×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Bluejay Diagnostics, Inc. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

BJDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
BJDXBluejay Diagnostics, Inc.	$2.5M	20
POASPhaos Technology Holdings (Cayman) Ltd.	$2.7M	2
IVFINVO Fertility, Inc.	$2.3M	34
ADGMAdagio Medical Holdings, Inc.	$2.3M	29
AIDX20/20 Biolabs, Inc.	$2.8M	3
ICCMIceCure Medical Ltd.	$3.0M	42
NUWENuwellis, Inc.	$3.1M	15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bluejay Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BJDX news & analysis

Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness

Accesswire · 13 Oct 2026positive

Bluejay Diagnostics said it completed the establishment of a manufacturing site for Symphony cartridges, meeting a contractual milestone under its amended license agreement with Toray ahead of the October 23, 2026 deadline. The company said it is advancing toward regulatory submission and potential commercialization.

Why it matters — The site establishment marks progress in manufacturing readiness for Bluejay’s Symphony platform as it advances toward regulatory submission and potential commercialization.

Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients

Benzinga · 6 Oct 2026positive

Bluejay Diagnostics said it revealed foundational clinical data from its SYMON-II validation trial for its Symphony near-patient diagnostic platform.

Why it matters — The trial data relates to Bluejay’s platform for rapid biomarker testing in sepsis patients.

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Accesswire · 6 Oct 2026positive

Bluejay Diagnostics reported preliminary baseline characteristics from its SYMON-II clinical validation study, including 777 evaluable patients: 637 28-day survivors and 140 non-survivors. The overall 28-day mortality rate was approximately 18%, and the study is evaluating IL-6 as a biomarker associated with mortality risk in sepsis and septic shock.

Why it matters — The dataset is a milestone in Bluejay’s evaluation of the Symphony IL-6 Test as the company advances it toward regulatory submission.

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

GlobeNewsWire · 8 Sept 2026positive

Bluejay Diagnostics announced a partnership with Lovell Government Services to establish a federal distribution and co-marketing framework aimed at expanding access to U.S. federal healthcare markets, including the VA, DoD, and Military Health Systems, as well as other government healthcare channels.

Why it matters — This partnership could open new government distribution channels for Bluejay Diagnostics, potentially broadening its market reach within the federal healthcare sector.

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

GlobeNewsWire · 13 Aug 2026positive

Bluejay Diagnostics reported its financial results for the quarter ended June 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress. The company said its strengthened balance sheet supports advancement of the Symphony™ IL-6 test toward regulatory submission and commercialization.

Why it matters — A BJDX watcher would care because the update addresses the company's clinical, regulatory and manufacturing progress toward bringing Symphony™ IL-6 to regulatory submission and commercialization.

FAQ

Frequently asked questions about BJDX stock

How does Ticker Nerd's model rank BJDX?

As at 31 Oct 2026, Bluejay Diagnostics, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the BJDX stock forecast for 2030?

No analyst covering Bluejay Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BJDX are extrapolating price history, which says nothing about the business.

How has BJDX stock performed over the past year?

Bluejay Diagnostics, Inc. returned -93.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bluejay Diagnostics, Inc. do?

Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings.

What is the latest news on BJDX?

The most recent item we track (Accesswire, 13 Oct 2026): "Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness". Bluejay Diagnostics said it completed the establishment of a manufacturing site for Symphony cartridges, meeting a contractual milestone under its amended license agreement with Toray ahead of the October 23, 2026 deadline. The company said it is advancing toward regulatory submission and potential commercialization.

Company

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings. Its core Symphony platform combines an analyzer and single-use cartridges to process whole blood and detect key biomarkers, supporting timely assessment of inflammation, infection, and cardiac conditions. The company’s current product development includes the Symphony IL-6 test for monitoring disease progression in critical care, along with additional assays targeting myocardial infarction and congestive heart failure. Bluejay Diagnostics also develops point-of-care diagnostic products designed to give healthcare providers faster, practical insights at the bedside. Headquartered in Acton, Massachusetts, Bluejay Diagnostics Inc. serves the healthcare market through technologies aimed at improving diagnostic workflows and supporting informed clinical decision-making.

CEO Mr. Indranil Dey · 6 employees · United States · https://bluejaydx.com